Last reviewed · How we verify

Rimegepant (PF-07899801) (rimegepant-pf-07899801)

Pfizer Inc. · Phase 3 active Quality 0/100

Rimegepant (PF-07899801) (generic name: rimegepant-pf-07899801) is a drug developed by Pfizer Inc.. It is currently in Phase 3 development.

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine headaches.

At a glance

Generic namerimegepant-pf-07899801
SponsorPfizer Inc.
PhasePhase 3

Mechanism of action

Rimegepant works by blocking the CGRP receptor, which is involved in the dilation of blood vessels and transmission of pain signals during migraines. By inhibiting this pathway, it helps reduce the frequency and severity of migraine attacks.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rimegepant (PF-07899801)

What is Rimegepant (PF-07899801)?

Rimegepant (PF-07899801) (rimegepant-pf-07899801) is a pharmaceutical drug developed by Pfizer Inc..

How does Rimegepant (PF-07899801) work?

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine headaches.

Who makes Rimegepant (PF-07899801)?

Rimegepant (PF-07899801) is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of Rimegepant (PF-07899801)?

rimegepant-pf-07899801 is the generic (nonproprietary) name of Rimegepant (PF-07899801).

What development phase is Rimegepant (PF-07899801) in?

Rimegepant (PF-07899801) is in Phase 3.

Related